Home » Newsletters » BioWorld Science

BioWorld Science

June 14, 2010

View Archived Issues

New inhibitors of TNF-alpha release disclosed

Actelion identifies new antimalarial agents

NeuroSearch describes new monoamine reuptake inhibitors

Ortho-McNeil-Janssen and Addex claim new mGlu2 receptor modulators

FDA grants fast track status to Collegium's tamper-resistant COL-172

Phase III apixaban trial closed early due to clear evidence of efficacy

Dystrophin-based gene therapy evaluated in Duchenne's muscular dystrophy

Dainippon Sumitomo Pharma discloses last year's highlights

MRX-4 improves several symptoms of grass pollen allergy

Trials suggest dasatinib or nilotinib could replace imatinib as first-line CML therapy

ANR-94 is active in rodent models of Parkinson's disease

Cediranib to enter phase II trial in advanced biliary tract cancers

Onset advances COL-177 and COL-179 for skin conditions

Pfizer and Eisai to launch Lyrica in Japan for postherpetic neuralgia

MannKind's Afrezza noninferior to lispro in type 1 diabetes

FDA lifts clinical hold on Repros Therapeutics' Proellex

Human Genome Sciences submits BLA to FDA for Benlysta

Preliminary phase II data released on Surfaxin in children with ARF

Idenix begins phase I/II trial of IDX-320 in chronic hepatitis C

PurGenesis begins phase IIa PUR-0110 trial in distal ulcerative colitis

Cadila Healthcare launches Vaxiflu-S H1N1 vaccine in India

MonoSol Rx and APR Applied Pharma Research expand collaboration

RXi confirms new therapeutic strategy for novel RNAi technology

Health Canada approves Novartis' Menveo vaccine

FDA extends PDUFA date for Acthar sNDA for infantile spasms

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 9, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...
News in brief
BioWorld Asia
BioWorld Asia briefs for Feb. 3, 2026